Sign In
Buy SKYE
$0.770
+0.0563 (+7.89%)
At Close: Jun 03, 2026
These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?
02:30pm, Friday, 19'th Apr 2024
Small-cap stocks tend to outperform their larger brethren over time. After several years of underperformance, it looked like the little guys were going to start winning again.
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
01:19pm, Tuesday, 16'th Apr 2024
Investors looking for a white-knuckle ride can easily find one by buying biotech stocks. There is a certain thrill in investing in a company making actual life-or-death decisions with drugs.
Skye Bioscience Uplists to The Nasdaq Global Market
08:00am, Wednesday, 10'th Apr 2024
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commer
Skye Bioscience Announces $40 Million Private Placement Equity Financing
09:20am, Monday, 11'th Mar 2024
Financing expected to fund strategic expansion of obesity clinical development and extend operating runway beyond 2026 San Diego, California--(Newsfile Corp. - March 11, 2024) - Skye Bioscience, Inc.
All Three of Our Analysts Agree
08:02pm, Friday, 08'th Mar 2024
Personalized health screening from a “smart toilet”
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
07:00am, Monday, 04'th Mar 2024
SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercial
SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company”), a clinical-stage biotechnology company focused on the discovery, development and commercia
Skye Bioscience to Present at Oppenheimer Investor Conference
07:00am, Wednesday, 07'th Feb 2024
San Diego, California--(Newsfile Corp. - February 7, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a clinical-stage biotechnology company focused on the discovery, development and commercializ
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing
08:00am, Monday, 29'th Jan 2024
Financing co-led by a leading life science investor and 5AM Ventures expected to fully fund obesity Phase 2 trial assessing nimacimab, Skye's differentiated peripheral CB1 inhibitor, in combination wi
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease
07:00am, Tuesday, 09'th Jan 2024
Phase 2 trial to assess impact of peripherally-acting CB1 inhibitor on weight loss and metabolic biomarkers related to co-morbid obesity and chronic kidney disease San Francisco, California--(Newsfile
Skye Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab
07:00am, Monday, 11'th Dec 2023
Skye files IND with FDA Division of Diabetes, Lipid Disorders and Obesity Phase 2 study in patients with obesity and chronic kidney disease planned to initiate in first half of 2024 SAN DIEGO, Dec. 11
Skye Bioscience Responds to OTC Markets Promotional Policy
05:14pm, Friday, 08'th Dec 2023
San Diego, California--(Newsfile Corp. - December 8, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing drugs targeting the endocannabinoid syst
San Diego, California and Johannesburg, South Africa--(Newsfile Corp. - December 5, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing drugs targeting the endoca
Skye Bioscience Treats First Patient in Glaucoma Phase 2 Study of SBI-100 Ophthalmic Emulsion
07:00am, Tuesday, 28'th Nov 2023
SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing drugs targeting the endocannabinoid system, focusing on
Skye Bioscience to Present at BTIG Ophthalmology Day and OIS XIII Ophthalmology Innovation Summit
07:00am, Tuesday, 21'st Nov 2023
San Diego, California--(Newsfile Corp. - November 21, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing drugs targeting the endocannabinoid system to address di
